Glucotrack Inc. designs, develops and commercializes technologies for people with diabetes and is focused on a long-term implantable continuous blood glucose monitor (CBGM). The company says its CBGM continually measures blood glucose with no on-body wearable component and requires minimal calibration. The article describes the device as having sensor longevity of "more than years." Glucotrack has moved toward first-in-human clinical trials and says it has made significant progress in CBGM development this year. To support that work it secured funding intended to increase financial flexibility as it embarks on human trials. Investor and longtime backer John Ballantyne commented that the company’s evolution in technology and focus has accelerated development and could be disruptive in the diabetes market.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2024